Search results
Showing 1401 to 1450 of 4138 results for patient
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
This document contains advice to help you access treatments and care that NICE has recommended
Wireless capsule endoscopy for investigation of the small bowel (IPG101)
Evidence-based recommendations on wireless capsule endoscopy for investigation of the small bowel. This involves the person swallowing a small capsule containing a tiny camera that takes pictures as it passes through the body.
View recommendations for IPG101Show all sections
Sections for IPG101
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 25 September 2026
Irreversible electroporation for treating renal cancer (IPG443)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for IPG443Show all sections
Sections for IPG443
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)
Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.
Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Stretta System for gastro-oesophageal reflux disease (MIB74)
NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
This indicator covers the proportion of new cases of cancer with stage at diagnosis recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG02
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients...
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)
Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.
Irreversible electroporation for primary liver cancer (IPG664)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for IPG664Show all sections
Diabetes: structured education within 12 months of diagnosis (IND11)
This indicator covers the proportion of adults with diabetes referred to a structured education programme within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG14
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Bronchoscopic thermal vapour ablation for upper-lobe emphysema (IPG652)
Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults. This involves using steam to destroy the diseased part of the lung.
View recommendations for IPG652Show all sections
Trabecular stent bypass microsurgery for open-angle glaucoma (IPG575)
Evidence-based recommendations on trabecular stent bypass microsurgery for open-angle glaucoma. This involves inserting a hollow metal tube (stent) into the eye, to improve drainage of fluid from the eye.
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
Gynaecological conditions: rates of endometrial ablation (heavy menstrual bleeding) (IND59)
This indicator covers rates of endometrial ablation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG78
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for IPG423Show all sections
Sections for IPG423
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Technology appraisal submission templates and supporting documents
All the templates and supporting documents you need to make a technology appraisals submission with NICE.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Renal and ureteric stones: assessment and management (NG118)
This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.
Evidence-based recommendations on endovascular stent-grafting of popliteal aneurysms. This involves inserting a ‘stent-graft’ device through the femoral artery (in the groin) lining the inside of the aneurysm.
View recommendations for IPG390Show all sections
Sections for IPG390
Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.
View recommendations for IPG707Show all sections
Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)
NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.
View recommendations for IPG642Show all sections
Find out more about the types of organisations that can register to be a stakeholder at NICE.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.
Multiple long-term conditions: multimorbidity register (IND205)
This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184
Stroke and ischaemic attack: early supported discharge (IND32)
This indicator covers the proportion of people who had a stroke that are supported by a skilled stroke early supported discharge team. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG49